Aerocrine Achieves Record Sales For The 4th Quarter And Full Year
Regulatory News:
“Measuring FeNO is the only noninvasive pulmonary function test allowing (1) detecting, (2) quantifying and (3) monitoring changes in inflammatory processes during the course of various respiratory disorders, including corticosensitive asthma” Aerocrine (STO:AEROB)
January – December 2014
· Net sales increased by 22% to SEK 166.2m (136.2)*. Adjusted for exchange rates, net sales increased by 16%.
Help employers find you! Check out all the jobs and post your resume.
“Measuring FeNO is the only noninvasive pulmonary function test allowing (1) detecting, (2) quantifying and (3) monitoring changes in inflammatory processes during the course of various respiratory disorders, including corticosensitive asthma” Aerocrine (STO:AEROB)
January – December 2014
· Net sales increased by 22% to SEK 166.2m (136.2)*. Adjusted for exchange rates, net sales increased by 16%.
Help employers find you! Check out all the jobs and post your resume.